AtriCure, Inc. (NASDAQ:ATRC) Insider Justin J. Noznesky Sells 1,500 Shares

AtriCure, Inc. (NASDAQ:ATRCGet Free Report) insider Justin J. Noznesky sold 1,500 shares of the firm’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $30.39, for a total transaction of $45,585.00. Following the sale, the insider now owns 72,784 shares in the company, valued at approximately $2,211,905.76. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

AtriCure Price Performance

Shares of AtriCure stock opened at $26.48 on Thursday. The firm has a market cap of $1.28 billion, a PE ratio of -40.12 and a beta of 1.38. AtriCure, Inc. has a 12-month low of $26.15 and a 12-month high of $59.61. The company has a quick ratio of 2.66, a current ratio of 3.57 and a debt-to-equity ratio of 0.15. The company’s fifty day simple moving average is $32.88 and its two-hundred day simple moving average is $35.72.

AtriCure (NASDAQ:ATRCGet Free Report) last announced its quarterly earnings results on Thursday, February 15th. The medical device company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01. The business had revenue of $106.50 million for the quarter, compared to analyst estimates of $103.68 million. AtriCure had a negative net margin of 7.62% and a negative return on equity of 7.55%. The company’s revenue was up 21.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.09) EPS. As a group, equities analysts expect that AtriCure, Inc. will post -0.71 EPS for the current year.

Institutional Investors Weigh In On AtriCure

A number of large investors have recently added to or reduced their stakes in the company. Invesco Ltd. boosted its stake in shares of AtriCure by 17.5% during the 1st quarter. Invesco Ltd. now owns 2,865,409 shares of the medical device company’s stock valued at $188,171,000 after purchasing an additional 427,792 shares in the last quarter. First Light Asset Management LLC boosted its stake in shares of AtriCure by 35.8% during the 1st quarter. First Light Asset Management LLC now owns 1,364,812 shares of the medical device company’s stock valued at $89,627,000 after purchasing an additional 359,823 shares in the last quarter. Norges Bank bought a new stake in shares of AtriCure during the 4th quarter valued at about $15,621,000. Nuveen Asset Management LLC lifted its position in AtriCure by 41.2% during the 2nd quarter. Nuveen Asset Management LLC now owns 981,165 shares of the medical device company’s stock valued at $48,430,000 after acquiring an additional 286,481 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in AtriCure by 366.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 342,987 shares of the medical device company’s stock valued at $16,930,000 after acquiring an additional 269,454 shares during the period. Institutional investors own 99.11% of the company’s stock.

Analyst Ratings Changes

ATRC has been the topic of several research reports. Needham & Company LLC raised their price objective on shares of AtriCure from $44.00 to $46.00 and gave the company a “buy” rating in a research report on Friday, February 16th. StockNews.com lowered shares of AtriCure from a “hold” rating to a “sell” rating in a report on Wednesday, March 27th. UBS Group increased their target price on shares of AtriCure from $57.00 to $58.00 and gave the company a “buy” rating in a report on Friday, February 16th. Finally, Stifel Nicolaus reduced their target price on shares of AtriCure from $50.00 to $42.00 and set a “buy” rating on the stock in a report on Friday, February 16th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $55.57.

View Our Latest Analysis on AtriCure

AtriCure Company Profile

(Get Free Report)

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.

See Also

Insider Buying and Selling by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.